Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name onivyde Active substance irinotecan Therapeutic area Oncology Decision number P/0241/2023 PIP number EMEA-003416-PIP01-23 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of pancreatic cancer Route(s) of administration All routes of administration Contact for public enquiries Les Laboratoires ServierE-mail: mail.pip.enquiries@servier.comTel.: +33 155726000 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 14/06/2023 Compliance check done No Decision P/0241/2023 : EMA decision of 14 June 2023 on the granting of a product specific waiver for irinotecan (Onivyde), (EMEA-003416-PIP01-23)Reference Number: EMA/241942/2023 English (EN) (213.98 KB - PDF)First published: 10/07/2024 View Related medicine information onivyde Share this page